PTCT - PTC Therapeutics, Inc.
NEXT EARNINGS:
Apr 23, 2026
EPS Est: $-0.43
|
Rev Est: $222.5M
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$84.50
DETAILS
HIGH:
$120.00
LOW:
$50.00
MEDIAN:
$84.00
CONSENSUS:
$84.50
UPSIDE:
22.50%
Market Cap:
5.54B
Volume:
877,282
Avg Volume:
1,569,273
52 Week Range:
35.95-87.5
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.49
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
939
IPO Date:
2013-06-20
EPS (TTM):
8.58
P/E Ratio:
8.85
Revenue (TTM):
1.73B
Total Assets:
2.91B
Total Debt:
492.28M
Cash & Equiv:
984.65M
Rev Growth (5Y):
35.4%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
44.1%
Debt/Equity:
-2.40
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-19 | $-1.67 | $-0.21 | -695.2% | $164.7M | $247.0M | -33.3% |
| 2025-11-04 | $0.20 | $-1.19 | +116.8% | $211.0M | $281.5M | -25.0% |
| 2025-08-07 | $-0.83 | $-1.07 | +22.4% | $178.9M | $191.5M | -6.6% |
| 2025-05-06 | $10.04 | $-1.08 | +1029.6% | $1.2B | $372.6M | +215.6% |
| 2025-02-27 | $-0.24 | $-1.12 | +78.6% | $213.2M | $249.0M | -14.4% |
| 2024-11-07 | $-1.39 | $-1.54 | +9.7% | $196.8M | $190.5M | +3.3% |
| 2024-08-08 | $-1.16 | $-1.00 | -16.0% | $186.7M | $185.3M | +0.7% |
| 2024-04-25 | $-1.20 | $-1.21 | +0.8% | $210.1M | $170.4M | +23.3% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.73B | 806.78M | 937.82M | 698.80M | 538.59M | 380.77M | 306.98M | 264.73M | 194.39M | 82.70M | 36.77M | 22.96M |
| Net Income | 682.64M | (363.30M) | (626.60M) | (559.02M) | (523.90M) | (438.16M) | (251.58M) | (128.08M) | (79.00M) | (142.11M) | (170.45M) | (93.75M) |
| EPS | 8.58 | -4.73 | -8.37 | -7.79 | -7.43 | -6.64 | -4.27 | -2.75 | -2.02 | -4.17 | -5.07 | -2.97 |
| Total Assets | 2.91B | 1.71B | 1.90B | 1.71B | 1.94B | 2.21B | 1.62B | 1.12B | 391.65M | 269.35M | 368.04M | 333.22M |
| Total Debt | 492.28M | 2.47B | 2.23B | 1.46B | 1.27B | 420.44M | 328.03M | 153.01M | 144.97M | 98.22M | 94.61M | 0 |
| Cash & Equivalents | 984.65M | 779.71M | 594.00M | 279.83M | 189.72M | 208.81M | 288.03M | 227.59M | 191.25M | 231.67M | 338.93M | 315.24M |
| Operating Cash Flow | 711.20M | (107.69M) | (158.42M) | (356.65M) | (251.33M) | (194.07M) | (98.64M) | (27.64M) | (10.06M) | (103.57M) | (124.34M) | (57.27M) |
| Free Cash Flow | 702.34M | (181.94M) | (279.04M) | (509.11M) | (336.66M) | (250.05M) | (144.08M) | (43.17M) | (13.16M) | (105.34M) | (127.06M) | (61.94M) |
| FCF per Share | 8.83 | -2.37 | -3.73 | -7.10 | -4.78 | -3.79 | -2.45 | -0.93 | -0.34 | -3.09 | -3.78 | -1.96 |
| Book Value | (205.31M) | (1.10B) | (818.55M) | (347.09M) | 1.44M | 481.98M | 594.33M | 350.73M | 156.44M | 119.58M | 298.47M | 298.47M |
| Cash & ST Investments | 1.95B | 1.14B | 876.74M | 410.70M | 773.38M | 1.10B | 686.56M | 227.59M | 191.25M | 231.67M | 338.93M | 315.24M |
| ROC Equity | N/A | N/A | N/A | N/A | -364.33 | -0.91 | -0.42 | -0.37 | -0.50 | -1.19 | -0.57 | -0.31 |